10/29/01 17:38 2603 228 4730 10/29/2001 17:30 FAX 18179738923 that of a subjecting this short distance PCR; and subjecting

the second set of amplification products to two-dimensional gel electrophoresis to produce

a characteristic spot pattern for a specific mutation in the BRCA1 gene.-

Please amend daim 4 as follows:

-4. (Amended) Test kits for enabling BRCA1 gene testing comprising primer per QUENCES solumn, mixed in about 20mM of Tris-HCI, 50mM KCI. 25pM of dNTP and 5% formamide.-

Certification

USSN 09/306,333 October 26, 2001--Viju et al

I hereby certify that the attached amendment document is being facsimile transmitted to the USPTO under date of October 26, 2001.

Holly Foots

RINES & RINES

81 North State Street

Concord, NH 03301

17037465180

1

Amendment D

Paper No. 16

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Jan Vijg

Serial No.: 09/306,333

Filed: May 6, 1999

Group Art Unit: 1655

Examiner: Souaya, J.

For: BRCA1 and hMLH1 Gene Primer Sequences And Method For Testing

* * *

Hon. Commissioner of Patents and Trademarks Washington, DC 20231

Please amend claim 10 as follows:

500

(,\

primers capable of amplifying the entire coding sequence of the BRCA1 genes; amplifying a test sample containing nucleotide sequences by long distance multiplex. PCR with exon fragments using primer sequences SEQ. ID Nos. 37-46, producing a first set of amplification products; subjecting this first set of amplification products to short distance multiplex PCR to produce a second set of amplification products with exon fragments using primer sequences SEQ ID Nos. 47-120 and with clamping and linking sequences therefor that include two clamping sequences for each of a plurality of the exon fragments, including clamping sequences SEQ ID Nos. 27 and 30, 29 and 31, 27 and 32, and 27 and 31, such effecting said short distance PCR; and subjecting the second set of amplification products to two-dimensional gel electrophoresis to produce a characteristic spot pattern for a specific mutation in the BRCA1 gene.

Please amend claim 4 as follows:

of what to

13/27

P.03

AND RINES

Test kits for enabling BRCA1 gene testing comprising primers SEQ. ID Nos. 47 120 mixed in about 20mM of Tris-HCl, 50mM KCl, 25pM of dNTP and 5%
formamide. —

Claim 11, line 2, cancel "and hMLH1".

REMARKS

It is desired to thank the Examiner for helpful suggestions for rendering the claims more definite and more definitive of applicant's provision of two clamps on primer exons that led to the unobvious result of vastly improved resolution of the electrophoresis patterns, as set forth in the earlier submitted Declaration.

Reconsideration and allowance accordingly now appear to be in order and are therefore respectfully requested.

Any costs incurred by this filing, including for any required extension(s) of time, petition for which is hereby made, may be charged to account No. 18-1425 of the undersigned attorneys.

Respectfully submitted,

RINES AND RINES

Robert H. Rines

Registration No. 15,932

Date: October 26, 2001 RINES AND RINES 81 North State Street Concord, NH 03301 Tel: (603) 228-0121